Answers are grounded in this paper and cite their sources.
Plumbago zeylanica L. (Chitrak) has been used within traditional medicine for many years. Due to it being reported to have antimicrobial, anti-inflammatory, antioxidant and wound-healing effects there has been an interest in creating topical products from this plant. Plumbago zeylanica contains various phytochemicals such as naphthoquinones, flavonoids, tannins, terpenoids and sterols. However, plumbagin in particular has attracted interest due to its biological activity. However, even though promising results were found using extracts of the plant or isolated compounds, this does not guarantee that the final product will be safe and effective. This narrative review will discuss the scientific reasoning behind creating a topical product from Plumbago zeylanica. This includes looking at aspects such as identification, standardisation, appearance, pH, rheology, homogeneity, release, skin distribution, biological activity, safety and stability. Whilst there is evidence to suggest further investigation could be done, especially regarding wound healing, the evidence is mainly pre-clinical. Future development should focus on creating a reproducible formulation, appropriate controls and ensuring that the biological activity relates to skin tolerance. Clinical trials will be needed before making definite claims about the therapeutic effect.
No takes yet. Share an insight, caveat, or question.
Randhirkumar et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: